Ryvu Therapeutics S.A. (WSE:RVU)
Poland · Delayed Price · Currency is PLN 18.96
-3.69 (-16.29%)
May 21, 2026, 5:04 PM CET
Ryvu Therapeutics Earnings Call Transcripts
Fiscal Year 2024
-
RVU120 is being evaluated in four Phase II studies for hematologic malignancies, showing early signs of efficacy and a favorable safety profile, especially in genetically defined AML and MDS cohorts. Enrollment and operational progress are strong, with key data readouts expected in the first half of 2025.